Increased eosinophil counts have been recognised to be linked to asthma severity and are a risk factor for asthma exacerbations. Therefore, decreasing eosinophil count by targeting the interleukin-5-mediated signalling pathway could help to reduce airway inflammation and improve asthma treatment control. In The Lancet Respiratory Medicine, Mario Castro and colleagues1 report data from two large, randomised, placebo-controlled trials, in which reslizumab, a neutralising monoclonal antibody for interleukin 5, was safe and effective in patients with severe eosinophilic asthma.
Recent Posts
- CXCL16 knockout inhibit asthma airway inflammation by suppressing H2-DM molecular mediated antigen presentation
- Exposure to volatile organic compounds and chronic respiratory disease mortality, a case-cohort study
- Beneficial effects of pleuran on asthma control and respiratory tract-infection frequency in children with perennial asthma
- Microbial influencers: the airway microbiome’s role in asthma
- Lung CD4+ resident memory T cells use airway secretory cells to stimulate and regulate onset of allergic airway neutrophilic disease